News

Idera said that majority of its stockholders voted in favor of the adoption of the merger agreement with BioCryst. BioCryst will pay $6m as transaction-related expenses to Idera,

As per the cash-cum stock deal signed in early May, the Japanese pharma company offers to pay $30.33 in cash for each Shire share in addition to either

The agency said that the recall pertains to medicines which use valsartan supplied by China-based Zhejiang Huahai Pharmaceuticals. It revealed that the review was launched after Zhejiang Huahai

Apart from the approval of the UK marketing authorisation application, Alliance Pharma has also received the agency’s nod to market the prescription nausea drug under the brand name

The companies have also announced research collaboration for the development of five additional gene therapy products in neurological disorders. Benitec’s silence-and-replace gene therapy technology has been designed to deliver a

The Pennsylvania-based cannabinoid-based drug developer reported that the drug, which is delivered via a transdermal patch, could not achieve the target blood levels of 5 to 15ng/ml THC

The regulator has accepted the application for a type II variation to the marketing authorization for Rubracato include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian

The company will recruit around 450 patients in the double-blind, randomized, placebo-controlled, 48-week safety and efficacy trial. The patients will be randomized 1:1:1 to two different Anavex 2-73

As per terms of the deal, Juniper will purchase all outstanding shares of Juniper by paying $11.50 per share in cash. Juniper’s core businesses include Crinone (progesterone gel)